A detailed history of Bank Of America Corp transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Bank Of America Corp holds 66,489 shares of URGN stock, worth $767,947. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,489
Previous 66,086 0.61%
Holding current value
$767,947
Previous $1.11 Million 23.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.7 - $17.92 $5,118 - $7,221
403 Added 0.61%
66,489 $844,000
Q2 2024

Aug 14, 2024

BUY
$12.72 - $19.2 $165,652 - $250,041
13,023 Added 24.54%
66,086 $1.11 Million
Q1 2024

May 15, 2024

SELL
$13.81 - $19.33 $256,879 - $359,557
-18,601 Reduced 25.96%
53,063 $795,000
Q4 2023

Feb 14, 2024

BUY
$10.87 - $15.93 $435,723 - $638,554
40,085 Added 126.94%
71,664 $1.07 Million
Q2 2023

Aug 14, 2023

SELL
$8.75 - $14.29 $866,565 - $1.42 Million
-99,036 Reduced 75.82%
31,579 $326,000
Q1 2023

May 12, 2023

BUY
$7.99 - $11.02 $81,010 - $111,731
10,139 Added 8.42%
130,615 $1.21 Million
Q4 2022

Feb 10, 2023

BUY
$7.55 - $11.96 $3,050 - $4,831
404 Added 0.34%
120,476 $1.07 Million
Q3 2022

Nov 14, 2022

SELL
$7.21 - $9.41 $25,487 - $33,264
-3,535 Reduced 2.86%
120,072 $999,000
Q2 2022

Aug 12, 2022

SELL
$5.12 - $8.74 $24,115 - $41,165
-4,710 Reduced 3.67%
123,607 $1.01 Million
Q1 2022

May 16, 2022

BUY
$5.92 - $9.73 $515,365 - $847,045
87,055 Added 210.98%
128,317 $1.12 Million
Q4 2021

Feb 08, 2022

BUY
$9.03 - $19.13 $42,612 - $90,274
4,719 Added 12.91%
41,262 $392,000
Q3 2021

Nov 15, 2021

SELL
$14.31 - $18.39 $759,746 - $976,361
-53,092 Reduced 59.23%
36,543 $614,000
Q2 2021

Sep 13, 2021

BUY
$15.2 - $20.94 $1.36 Million - $1.88 Million
89,635 New
89,635 $1.37 Million

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $263M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.